Filing Flows › Vivos Therapeutics (VVOS) › Q2 2025
Vivos Therapeutics (VVOS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 19, 2025
Vivos Therapeutics (VVOS) reported revenue of $3.8M for the second quarter 2025 (Q2 2025), -6% from a year earlier and +27% from the quarter before. Operating margin was -127.4%, net loss $5.0M (131.2% of revenue).
Vivos Therapeutics, Q2 2025: revenue $3.8M (-6% year over year), operating margin -127.4%, net loss $5.0M, operating cash flow −$3.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.8M | +27% | -6% |
| Operating profit | −$4.9M | — | — |
| Net earnings | −$5.0M | — | — |
| Operating cash flow | −$3.5M | — | — |
What changed
Revenue was $3.8M in Q2 2025, down 6% year over year and up 27% from the previous quarter. Appliances was the largest line at 27% of revenue. VIP lost $1.0M year over year (down 89%), 446% of the total change.
Gross margin was 55.2%, down 10.2 points from a year earlier. Operating costs exceeded revenue by $4.9M, an operating margin of -127.4%. Operating expenses grew 52% against a revenue fall of 6%. The fastest-growing cost line was Other operating costs (+111%). The quarter ended with a net loss of $5.0M, wider than the previous quarter's $3.9M loss.
Operating cash flow was −$3.5M. Non-cash charges added back $306K of depreciation and amortization and $242K of share-based compensation. Working capital and other items added $1.0M. Capital expenditures of $771K exceeded it, leaving free cash flow of −$4.3M.
Questions
What was Vivos Therapeutics' revenue in the second quarter 2025?
Vivos Therapeutics (VVOS) reported revenue of $3.8M for the second quarter 2025 (Q2 2025), -6% from a year earlier and +27% from the quarter before.
Was Vivos Therapeutics profitable in the second quarter 2025?
Operating loss was $4.9M (-127.4% of revenue) and net loss $5.0M.
Source: Vivos Therapeutics 10-Q on SEC EDGAR.